Gus Bilirakis actually said...

"Would it improve the standard of care to have these indications on the label, such as ensuring correct dosage and access to insurance reimbursement?"

"I think the best way to do that is to ask the FDA or direct the FDA by legislation, or statute, or regulation changes, to allow that communication to go forward."

"Why would you approve a drug with 5 times as much hydrocodone as Vicodin with no abuse-deterrent properties?"

"But why wouldn't we make sure that it has abuse deterrent prior to approval?"